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Abstract
The Varicella zoster virus is a human pathogen which 
causes Varicella after primary infection and herpes zoster after 
secondary reactivation. Both disease manifestations can occur at 
any age; however, Varicella is seen more commonly in children 
whilst herpes zoster is mainly observed in the elderly. Although 
uncommon, disease complications secondary to Varicella may 
be severe and life-threatening especially at the extremes of age, 
during pregnancy and in the immunocompromised.  Attenuated 
Varicella vaccines have been successfully formulated to prevent 
Varicella and its complications and are part of the routine 
childhood immunisation programmes in several countries 
including the US, Canada, Germany and Australia. This review 
discusses the epidemiology of Varicella, the clinical presentation 
and management of Varicella zoster virus infections and the 
potential of preventing Varicella and herpes zoster through 
immunisation.
Introduction
Varicella zoster virus causes Varicella (chickenpox) after 
primary infection and herpes zoster (shingles) after endogenous 
reactivation. The virus contains a double stranded DNA genome 
and is a member of the Herpesviridae family. Herpes viruses 
are characterised by the persistence of infection after primary 
infection, a property known as latency. Cell-mediated immunity 
is critical in clearing the infection and in preventing secondary 
reactivation.1 
Varicella, a highly contagious disease with an attack 
rate approaching >85% after exposure2, is usually benign in 
immunocompetent 1-12 year old children but can be severe in 
adults and life threatening in the immunocompromised.3,4 Live 
attenuated vaccines containing the Oka strain of the Varicella 
zoster virus, were designed in the 1970s and subsequently 
licensed for the prevention of Varicella in healthy children and 
adults, since the 1980s.5 
This review discusses the epidemiology of Varicella in 
Malta, the manifestations and management of infections caused 




Humans are the only known hosts for the Varicella zoster 
virus which exists in only one recognised serotype.  The 
incubation period after inoculation is usually 14-16 days, but 
may vary from 10-21 days.1 Viral shedding occurs from the 
nasopharynx via droplets and aerosols and from the skin 
lesions.1 The contagious period starts 1-2 days before the 
appearance of the exanthem and lasts till all the vesicles have 
crusted, usually within 5-7 days.6 
The incidence of Varicella in temperate climates is 13-16 
cases per 1000 people per year6 and is highest in 1-9 year 
old children, although there has been an increase in children 
younger than 5 years due to attendance at child-care centres.7 
By contrast, in tropical climates, the attack rate of Varicella is 
higher in adults.8 In both temperate and most tropical climates 
the incidence of Varicella shows pronounced seasonality with 
peaks occurring in the cooler months during winter or spring.8,9 
In temperate climates epidemics of Varicella have been reported 
to occur every 2-5 years.9,10 The overall case-fatality rate in 
developed countries is 2-4 per 100,000 cases with the risk of 
dying being highest at the extremes of age.6 The rate of hospital 
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admission for all ages is 2–6 per 100,000 population with most 
admissions occurring in children.6,11 
In contrast to other European countries, notification of 
Varicella in Malta is mandatory. The number of notified cases 
over the last 30 years varied from year to year12 reflecting 
the natural cycles of Varicella as well as differences in case 
ascertainment and reporting (Figure 1). The average incidence 
of Varicella in Malta (from 1999 – 2005) was 9/10,000 
population per year. By comparison the burden of Varicella in 
other countries was reported to be 25 per 10,000 in England 
and Wales, 13 per 10,000 in The Netherlands, and 21 per 
10,000 in Portugal.13 Such differences could be explained by 
variability in surveillance, health care systems and completeness 
of ascertainment between countries.6 
A formulation of the Varicella zoster virus vaccine was 
introduced on the private market in Malta in 1998. Presently 
local uptake rates of this vaccine are unknown as such data 
are not being collected. No adverse drug reactions (ADRs) 
associated with the administration of this Varicella vaccine 
formulation have been reported to the Medicines Authority since 
the set up of the ADR database in 2004. Analysis of the number 
of notified cases after 1998 does not show the expected decline in 
the disease burden of Varicella over the subsequent years. This 
is because control and elimination of the disease is dependent 
on the ability to vaccinate a herd immune threshold the size of 
which can be determined by mathematical modelling, as has 
been calculated for those countries taking part in the European 
sero-epidemiology network 2 (ESEN2) project which collected 
serological surveillance data on vaccine preventable diseases, 
including Varicella.14 
Clinical manifestations
Varicella is characterised by the appearance of a generalised 
pruritic vesicular rash, typically consisting of 250–500 lesions, 
associated with constitutional symptoms including headache, 
malaise, loss of appetite and mild fever. Lesions, which typically 
appear in crops, are more concentrated centrally, on the trunk 
and face, than on the limbs. The crusts which form on the 
healing lesions fall off after 1-2 weeks and frequently leave 
areas of hypo- or hyperpigmentation, which may persist for 
months, or permanent scars15. Complications include bacterial 
superinfection of the skin lesions, which are frequently 
caused by Group A streptococcus and seen in >5% of children, 
arthritis, osteomyelitis, thrombocytopenia, pneumonitis, 
hepatitis and central nervous system manifestations including 
cerebellar ataxia, meningoencephalitis and intracranial 
vasculitis.16 Pneumonia is more often seen in adults and during 
pregnancy.3,16 Immunocompromised children have an increased 
risk of developing progressive severe Varicella with visceral 
dissemination.17 
Following a period of latency in the dorsal root ganglia, 
reactivation results in herpes zoster, characterised by the 
appearance of vesicles in a dermatomal distribution. The 
incidence of herpes zoster is 74 per 100,000 in children below      
Figure 1: Number of notified cases of Varicella in Malta (1978 – 2007)
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the age of 10 years but reaches up to 1200 per 100,000 in 
people >75 years, who are at an increased risk of postherpetic 
neuralgia.18 Severe herpes zoster, affecting an unusual site, 
or appearing in a multi-dermatomal distribution and with a 
potential for visceral involvement, may occur in individuals who 
are immunocompromised such as those receiving chemotherapy, 
especially those with leukaemia, those on high dose steroids and 
in patients with the Acquired Immunodeficiency syndrome 
(AIDS).1,19 
Maternal Varicella in the first 20 weeks of pregnancy results 
in Varicella embryopathy in 2% of the fetuses.20 The congenital 
Varicella syndrome is characterised by limb atrophy, scarring of 
the skin of the extremities, chorioretinitis, cataracts and brain 
abnormalities which are associated with developmental delay 
and a poor outlook.20 Maternal Varicella developing 5 days 
before to 2 days following delivery may result in severe neonatal 
Varicella which has a mortality rate of 30%.21 
Diagnosis
Diagnosis is usually established clinically from the 
characteristic rash which is easily differentiated from that of 
small pox from the typical stages of development of the skin 
lesions. Varicella–zoster specific IgM may be detectable as 
early as 1-2 days before the appearance of the rash, although 
the absence of antibodies does not rule out the diagnosis.6 IgG 
antibodies appear shortly after the IgM response and persist 
throughout lifetime6. For fatal, severe or atypical illness the 
Varicella zoster virus may be identified from skin scrapings by 
PCR22 or by immunofluorescence techniques.23
Treatment
In the majority of cases Varicella in immunocompetent 
children is a self-limiting disease and symptomatic treatment, 
which includes temperature control, alleviation of pruritus and 
adequate hydration, is usually sufficient. Non-steroidal anti-
inflammatory drugs are not recommended for symptomatic 
relief due to the possible associated increased risk of invasive 
Streptococcus pyogenes infections.24 The administration of 
antibiotics is necessary when treating secondary bacterial 
infections. Antivirals, such as acyclovir, are mandatory for 
high risk individuals, including immunocompromised hosts 
and newborns with transplacentally-acquired Varicella, and in 




Varicella-susceptible individuals, who are at a high risk of 
developing severe or disseminated Varicella, may be given human 
Varicella zoster immunoglobulin (VZIG) after a significant 
exposure to the virus. Susceptible high risk individuals include 
the immunocompromised, non-immune pregnant women and 
newborn infants exposed to maternal varicella1.
Active immunisation
An attenuated Varicella zoster vaccine was developed from 
an Oka strain of the wild type Varicella zoster virus in Japan in 
1974 by Takahashi and colleagues.25 Subsequently this vaccine 
master seed was licensed out to various manufacturers and 
currently there are three preparations of the Oka strain Varicella 
zoster virus vaccine in use: OkavaxTM, manufactured by the 
Research Foundation for Microbial Diseases of Osaka University 
(BIKEN) in Osaka, Japan (distributed by Sanofi Pasteur, Lyon, 
France), VarivaxTM (Merck & Co., Inc., Whitehouse Station, 
New Jersey, USA), and VarilrixTM (GlaxoSmithKline Biologicals, 
Rixensart, Belgium). Both VarivaxTM and VarilrixTM are licensed 
in Europe for use from the age of 12 months, with VarilrixTM 
being licensed from the age of 9 months in some countries. 
Since VarilrixTM is currently the only Varicella zoster virus 
vaccine marketed in Malta, only data from clinical trials which 
investigated this vaccine will be discussed. VarilrixTM will be 
referred to as the Oka-recombinant immunotoxin (Oka-RIT) 
vaccine for the purpose of this article.
Immunogenicity
The administration of a single subcutaneous dose of the 
Oka-RIT vaccine, which contains a minimum of 1995 plaque 
forming units (PFU) of the Oka-vaccine strain, in 12 month 
to 12 year old children results in a seroconversion rate >98%, 
using a glycoprotein Enzyme-linked Immunosorbent Assay 
(gpELISA).26 Post immunisation Varicella zoster antibodies 
persist for at least up to 7 years in children vaccinated at 12–15 
months of age.26 In June 2006, the US Advisory Committee 
on Immunization Practices (ACIP) recommended two doses 
of a similar Oka-strain (Oka/Merck) vaccine, VarivaxTM, in 
children <13 years of age since, as despite an efficacy rate of 
85%, a single dose was not enough to prevent outbreaks of 
breakthrough Varicella (i.e. Varicella occurring in previously 
vaccinated individuals).27 Such a recommendation might not be 
applicable to countries without a universal Varicella vaccination 
programme as ongoing exposure to wild-type virus might result 
in natural boosting of cellular immunity and a subsequent longer 
duration of protection.28 In adolescents ≥13 years and in adults, 
a two-dose schedule of the Oka-RIT vaccine at an interval of 
6-10 weeks, results in a seroconversion rate of 100% after the 
second dose.26 The Oka-RIT vaccine may be safely administered 
concurrently, but at a different site, with the combined measles, 
mumps and rubella (MMR) vaccine as studies have shown that 
there is no compromise of the immunogenicities of any of the 
four vaccine antigens with simultaneous administration of 
these vaccines.26 
Quadrivalent vaccine formulations incorporating the 
measles, mumps, rubella and Varicella (MMRV) attenuated 
viruses have been recently licensed for use in children. Currently 
there are two licensed MMRV vaccine preparations: ProQuadTM 
(Merck & Co., Whitehouse station, New Jersey, USA) licensed 
from the age of 12 months to 12 years in the US and Priorix 
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TetraTM (GlaxoSmithKline Biologicals, Rixensart, Belgium) 
licensed in Germany and Australia for immunisation of 1-2 year 
old children. A higher dose of the Oka-strain Varicella virus had 
to be incorporated in both combination vaccine formulations 
in order to achieve an immune response comparable to that 
induced by the monovalent Varicella vaccines. 
Vaccine use
In 2004, the European Working Group on Varicella 
(EuroVar) recommended Varicella vaccination for all healthy 
12-18 month old children and all susceptible children <13 years, 
in addition to the routine vaccination of susceptible children ≥13 
years old and adults.29 Pre-exposure vaccination is advisable in 
susceptible healthcare workers, laboratory staff and contacts 
of immunocompromised individuals.29 When administered 
within 96 hours from exposure, the Oka-RIT vaccine is 80-90% 
effective in preventing moderate to severe disease in Varicella 
naïve individuals.26 Post-exposure prophylaxis is possible since, 
the Oka vaccine strain induces an immune response prior the 
clinical viraemia with the wild type virus and thus helps to abort 
or modify clinical disease.  
There are currently no data on the impact of the Varicella 
vaccination on the incidence of herpes zoster several decades 
after vaccination. However a high dose Oka-strain virus 
vaccine (ZostavaxTM, Merck & Co. Inc., Whitehouse Station, 
New Jersey, USA) has been shown to reduce the incidence and 
morbidity from herpes zoster and postherpetic neuralgia in 
elderly people.30
Vaccination with the Oka-RIT vaccine is contraindicated 
in individuals with hypersensitivity to any of the vaccine 
constituents, during pregnancy and lactation, whilst on high 
dose systemic corticosteroids (amounting to >1mg/kg/day of 
prednisolone or its equivalent or 20mg/day if weight is >20kg) 
and in the immunocompromised, although the vaccine may be 
given with caution and under expert supervision in children 
with specific immunodeficiencies, such as in acute lymphoblastic 
leukaemia in stable remission for 12 months.26 Following 
vaccination the use of salicylates in children and adolescents 
<16 years is not recommended because of the theoretical risk 
of Reye’s syndrome.31 
Adverse events
Erythema, swelling and pain at the injection site are the 
most frequently reported local side effects, occurring in 10%-
20% of vaccinees ≤12 years.26 Constitutional symptoms such 
as headache, fever and fatigue are also common. Rashes occur 
in 5% of vaccinees. Transmission of the vaccine virus following 
the appearance of a vesicular rash post immunisation was 
documented in only 3 individuals (who developed mild disease) 
after the administration of >30 million doses of the Oka/Merck 
vaccine used in the US.27 Vaccinees who develop a vesicular rash 
should however avoid contact with high risk individuals.
The rate of febrile convulsions of 9/10,000 reported in 12-23 
month old children, 7-10 days after receiving the combination 
MMRV formulation (ProQuadTM), has recently been identified 
to be higher than the rate of 4/10,000 observed in children 
immunised with the separate MMR and Varicella vaccine 
formulations.32 Because of this post-licensure surveillance data 
the US ACIP does not prefer the use of MMRV over separate 
injections of MMR and Varicella, any more.32 However both 
the MMRV and the separate MMR and Varicella vaccine 
formulations may still be used for immunising children. 
Conclusion and future directions
The disease burden of the Varicella zoster virus in countries 
without a universal Varicella vaccination schedule is high, with 
most episodes of hospitalisation, due to serious and potentially 
life-threatening and debilitating complications, occurring in 
healthy children. 
Safe and effective Varicella zoster vaccines are currently 
licensed in several countries for the prevention of Varicella 
from late infancy to adulthood and may be safely administered 
concurrently with other vaccines which are already part 
of the childhood immunisation schedule. The Varicella 
zoster vaccine already forms part of the national childhood 
vaccination programmes in Austria, Cyprus, Germany, Italy, 
Spain, Switzerland33, the US, Canada and Australia, however, 
economic issues will have a major bearing on the introduction 
of a ‘free of charge’ Varicella vaccine in the national childhood 
immunisation programme in Malta.  Immunising all children 
against Varicella would ultimately result in control of the spread 
of the disease, protection of high risk susceptible patients 
through herd immunity, a reduction in the cost of treating 
patients with Varicella and its complications and a decrease 
in societal costs from parents taking time off work to care for 
their children infected with Varicella. Following on from the 
occurrence of breakthrough Varicella after a single dose of 
the Varicella vaccine in children in the US, the introduction of 
routine Varicella vaccination for all healthy Maltese children and 
adolescents might eventually need to be followed by a booster 
dose to counteract the lack of natural boosting from wild-type 
Varicella. Surveillance of the Varicella vaccine uptake in Malta 
would be crucial in assessing the impact this vaccine would have 
on the disease burden of Varicella. In addition, the availability 
of a herpes zoster vaccine to prevent or modify herpes zoster 
and its complications in adults aged 60 years or older, would 
further aid in reducing the morbidity caused by the Varicella 
zoster virus.
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